The GINECO window-of-opportunity COLIBRI (NCT04256213) study provides compelling evidence that a neoadjuvant "priming" dose ...

Neoadjuvant pembrolizumab achieved a 71% pCR rate in desmoplastic melanoma, surpassing expectations for neoadjuvant anti–PD-1 treatment. The 3-year relapse-free survival rate was 74%, and the overall ...

Neoadjuvant immunotherapy plus chemotherapy shows a 35% pathological complete response rate and 49% major pathological response rate in LS-SCLC. Most patients achieved R0 surgical resection, with a 44 ...

Please provide your email address to receive an email when new articles are posted on . The addition of nivolumab to neoadjuvant chemotherapy significantly increased pathologic complete response among ...

Please provide your email address to receive an email when new articles are posted on . Most patients achieved complete response with dostarlimab alone. Further research is needed given the ...

New results from a clinical trial co-led by UCLA investigators demonstrate how treating desmoplastic melanoma, a rare and ...

The results of the phase 3 ATOMIC trial fired another volley in the ongoing debate over adjuvant vs neoadjuvant immunotherapy for patients with locally advanced colon cancer. But experts are divided ...

Investigators trialed injection of an immune-stimulating substance (poly-ICLC) into the prostate gland using MRI-ultrasound fusion technology in patients scheduled to undergo radical prostatectomy.

Nivolumab plus ipilimumab or relatlimab nearly doubled response rates compared to nivolumab alone in head and neck cancer. Patients with major pathologic responses had better disease-free and overall ...

Both survival and safety outcomes after neoadjuvant immunotherapy appear favorable for appropriate patients with muscle-invasive bladder cancer undergoing chemoradiation. Neoadjuvant immunotherapy in ...

In a national cohort study of patients with resectable head and neck squamous cell carcinoma (HNSCC), the number receiving neoadjuvant immunotherapy began to rise markedly in 2013, while use of ...

The KEYNOTE-671 trial showed a 71% 36-month overall survival rate with perioperative Keytruda, compared to 64% with placebo. FDA approvals for Keytruda, Imfinzi, and Opdivo in perioperative settings ...